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STATEMENT OF TRANSLATIONAL RELEVANCE
Oncolytic viruses (OV), such as those based on herpes simplex virus type 1 (HSV1), have and are being tested in clinical trials for malignant glioma. We have generated a novel tumor-specific OV (rQNestin34.5) and are in the process of testing it in a human clinical trial for recurrent malignant glioma. In this OV, a nestin promoter drives expression of a HSV1 viral gene needed for robust viral replication and glioma lysis. We have discovered that the nestin promoter becomes extensively methylated and silenced after glioma infection. Addition of demethylating drugs to rQNestin34.5 leads to re-expression of viral genes, enhanced viral replication and improved glioma lysis. This translates to significantly increased efficacy in animal models of gliomas. Therefore, demethylating agents, such as decitabine, may improve the clinical efficacy of rQNestin34.5 against human gliomas.
INTRODUCTION
Oncolytic viruses (OV) are either natural mutants or genetically engineered strains of viruses that replicate and lyse tumor cells in a relatively selective fashion (1). Although there are several types of OVs, those based on herpes simplex virus type 1 (HSV1) have been widely studied in animal models and in human clinical trials (2, 3) . Subjects have been reported to tolerate the treatment well, although evidence for efficacy awaits testing in phase 3 trials. Efficacy is predicated on sufficient replication and OV bio-distribution to permit direct cytotoxicity and/or antitumor immune responses to occur. In this context, evidence from clinical trials appears to show that replication needs to be improved for a sufficient therapeutic effect to occur (4, 5) .
In order to improve replication, efforts to understand how the OV and the host interact are needed. One of the intracellular mechanisms of defense against a viral infection lies in epigenetic silencing of viral genes. While for some viruses, such as EBV, methylation of CpG islands in genes and promoters is one mechanism for gene silencing (6) , for HSV1 the evidence for CpG methylation playing a major role has been controversial, with recent data showing that the HSV1 genome is not extensively methylated at CpG sites (7) (8) (9) .
Notwithstanding this, it is not known if oncolytic HSV1s (oHSV1), engineered with heterologous (such as tumor-specific) promoters, would be different. This is a significant question to explore since effective demethylating agents exist that could be utilized in a clinical trial with oHSV. 
Materials and Methods
Reagents -Dulbecco's modified minimal essential medium (DMEM), Neurobasal medium, Hank's Balanced Salt Solution (HBSS), penicillin and streptomycin, GlutaMax, B27 supplement were purchased from Invitrogen (Carlsbard, CA, USA). Human basic fibroblast growth factor (hEGF) and epidermal growth factor (hFGF) were purchased from R&D Systems, Inc (Minneapolis, MN, USA). VPA, 5-Azacytidine, and Decitabine (5-aza-2'-dexoxycytidine) were purchased from SIGMA Aldrich (St Louis, MO, USA).
Cell proliferation Kit I (MTT) was purchased from Rosh (Indianapolis, IN, USA) Cells and Medium -Human U87ΔEGFR glioma cells were maintained in DMEM supplemented with 2% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin.
Human primary OG02 and G169 gliomas were established from surgical specimens resected from glioblastoma patients and were grown as tumor spheres in medium consisting of Neurobasal medium with x1 GlutaMax, with B27 supplement (1Å~; Invitrogen), hFGF (20 ng/ml), hEGF (20 ng/ml), penicillin (100 U/ml), streptomycin (100 μg/ml). All cells were cultured at 37 °C in an atmosphere containing 5% carbon dioxide.
Virus replication assay -The oHSV, rQNestin34.5, was previously described (10) and replication assay were conducted as per previous publications (12) . Briefly, after incubation with VPA for 20h or 5-Aza for 2 days, cells were seeded onto 24-well plates at 2 × 10 When we analyzed this nestin promoter sequence, we realized that several CpG rich islands were present (Supplemental Figure 1) . This information thus may mean that expression of γ  34.5 could be limited by methylation of its promoter shortly after infection.
Demethylation of rQNestin34.5's ICP34.5 promoter. Based on the above finding, we hypothesized that this promoter would be methylated upon tumor cell infection and that treatment with demethylating agents could increase oHSV gene expression and replication.
In fact, analysis of this promoter region after infection confirmed that it is hypermethylated Figure 3A shows that oHSV alone led to 50% cell killing at a dose of 0.05 pfus in G169 and 0.5 pfus in OG02 primary glioma cells.
5-Aza alone led to a median effect on cell survival at a dose of approximately 4 μM for either cell (not shown). Chou-Talalay analyses were then performed (23, 24) . Figure 3B shows that there was very strong synergy for the majority of affected fractions after combination treatment with 5-Aza and oHSV. These results thus provided confirmation that oHSV and 5-Aza act in a synergistic fashion in mediating cytotoxic effects against glioma cells. Therefore, the addition of demethylating agents to rQNestin34.5 virotherapy provides a beneficial therapeutic effect in a preclinical experimental setting.
In vitro, we also showed that the histone deacetylase inhibitor, VPA, led to demethylation of the nestin promoter. Previously, we had showed that VPA significantly improved OV replication and survival of mice with orthopic glioma xenografts (10, 12) . The mechanism for this effect was reported by us to occur through VPA's action on reducing STAT1's activation of interferon signaling. We also have recently shown that VPA also (26, 27) . The finding of reducing the hypermethylation of the oHSV's heterologous promoter uncovers another mechanism that plays a role in VPA's improvement of rQNestin34.5 replication.
Recently, VPA has been reported to decrease DNA methyltransferases (DNMTs) protein levels and reduce DNMT enzyme activity (28) . The role of epigenetics and the significance of aberrant gene regulation in the etiology of cancer is a well-established phenomenon. The hallmark of cancer epigenetics is aberrant DNA methylation consisting of global hypomethylation and regional hypermethylation of tumor suppressor genes (TSGs) by DNMTs (29, 30) . Overexpression of DNMT1 and DNMT3B in gliomas leads to hypermethylation of various tumor suppressor genes, resulting in a lack of cell growth regulation and higher genomic instability. This hyper-activation of DNMTs may thus lead to reduced efficacy of oHSVs. In fact, there have been reports that the expression of transgenes in tumors after viral-mediated delivery decreased, but that 5-Aza and/or Trichostatin A reversed this, implying gene methylation as a silencing mechanism for oncolytic viruses in tumors (31) . However, the role of methylation in silencing HSV genes is controversial. Kubat et al reported that the HSV1 genome was not hypermethylated after infection of rabbit skin cells (9) . Our findings showed that the nestin promoter CpG islands were extensively methylated. Although this could be explained because it is heterologous, Figure 2 shows that the transcription of several oHSV genes was also 
enhanced by 5-Aza or VPA. One explanation may be that the enhanced transcription of the nestin promoter driven γ 1 34.5 gene also led to increased transcription of other viral genes.
The alternative explanation is that these epigenetic reagents demethylated CpG islands of endogenous HSV1 promoters, leading to the observed increased transcription. In fact, in support of the latter explanation, the methylation status of the endogenous ICP4 promoter in oHSV-infected glioma cells also showed extensive methylation with expected de-methylation by 5-Aza (data not shown).
Demethylating agents could also affect OV replication by reversing the hypermethylation status of promoter/enhancers of interferon and interferon response genes. However, this is unlikely to be operative in our model because we have observed that 5-Aza enhances rQNestin34.5 replication even in the human U87 glioma cell line that is interferon-insensitive (data not shown), because of deletion of chromosomal loci where such genes reside and not because of interferon gene promoter hypermethylation (32, 33) Instead, VSV action in breast cancer cells has been reported to be enhanced by DNA demethylating agents not because they demethylated the IRF5 and IRF7 promoters, but rather through another unknown mechanism (34) . To determine in vivo effects of the combination therapy on human glioma animal models we had to utilize athymic mice.
Possible effects of demethylating agents on T cells in immunocompetent animal models will thus require further experimentation, although we have minimized for this in our model by intratumoral, local administration of drug. In fact, to minimize possible systemic effects of demethylating agents and maximize effects on the oHSV itself, we also toxicity data in animals should be carried out to evaluate if Decitabine can be justifiably added to rQNestin34.5 in subsequent clinical trials, particularly since demethylating agents could reactivate latent viruses. In addition, the schedule of demethylating agent treatment with oHSV will need further detailed analysis.
There have been now several instances/reports of drugs that can be used to pharmacologically enhance viral oncolysis (35) . The mechanism of action of such pharmacologic enhancement is dependent on the drugs' mode of action. For instance, some will modulate the immune system to reduce immune cell-mediated clearance of injected OVs or OV-infected tumor cells. Other drugs will up-regulate tumor cell pathways that can be also utilized by the OV for improved replication. Still others will modulate the tumor microenvironment to facilitate OV distribution or survival. In this context, the findings in this report represent the first example of a drug that acts directly on the viral genome to improve its anticancer effect. As the field of epigenetic therapy progresses, it will be interesting to determine if other agents that act on other aspects of the epigenome will also modulate OV DNA to improve its replicative ability.
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